Wells Fargo Starts Omnicell (OMCL) at Market Perform
Tweet Send to a FriendGet Alerts OMCL Hot Sheet
Price: $18.81 +0.80%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade OMCL Now!
Wells Fargo initiates coverage on Omnicell (NASDAQ: OMCL) with a Market Perform and $18-$20 valuation target.
The firm comments, "The company has an estimated 25% share of the market for selling medication dispensing cabinets and related software to hospitals in the United States. More recently, it has expanded into equipment and consumables that institutional pharmacies use to package medications that are dispensed in long term care facilities. While we project organic top line growth around 10% and believe management may be downplaying the accretion from the recent acquisition of MTS, these shares have bounced significantly off of recent lows and the company is exposed to hospital capital spending that could be impacted in the event that the economy falls off the fiscal cliff. We prefer to wait for a better buying opportunity or more certainty around economic conditions."
For an analyst ratings summary and ratings history on Omnicell click here. For more ratings news on Omnicell click here.
Shares of Omnicell closed at $15.82 yesterday, with a 52 week range of $12.33-$17.94.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "The company has an estimated 25% share of the market for selling medication dispensing cabinets and related software to hospitals in the United States. More recently, it has expanded into equipment and consumables that institutional pharmacies use to package medications that are dispensed in long term care facilities. While we project organic top line growth around 10% and believe management may be downplaying the accretion from the recent acquisition of MTS, these shares have bounced significantly off of recent lows and the company is exposed to hospital capital spending that could be impacted in the event that the economy falls off the fiscal cliff. We prefer to wait for a better buying opportunity or more certainty around economic conditions."
For an analyst ratings summary and ratings history on Omnicell click here. For more ratings news on Omnicell click here.
Shares of Omnicell closed at $15.82 yesterday, with a 52 week range of $12.33-$17.94.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Barclays Starts SBA Communications (SBAC) at Overweight
- Barclays Starts Crown Castle (CCI) at Equalweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
